Adaptimmune Therapeutics (ADAP)

ADAP was delisted on the 27th of October, 2025.

• Market cap: $14.6M
• Sector: Healthcare
• Industry: Biotechnology

About: Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Employees: 506